Baxter Dual Luer Lock Cap Recall Due to Particulate Matter

|

Federal regulators have declared a Class I recall for two lots of protective caps used for IV sets after the manufacturer recognized the presence of particular matter in the packaging, which may pose a risk of infection and clotting for patients if it enters the blood stream.  

A Baxter Dual Luer Caps recall was announced by the FDA on September 19, due to the potential for particulate matter located in the caps to transfer into IV sets or stopcocks when not in use.

In the event that the particles did contaminate or transfer into the IV lines patients could suffer from pulmonary embolisms, myocardial infarction and even strokes. To date, no injuries have been reported.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

The affected Lauer Lock Caps are used as a protective cap on various access ports on medical devices that are not in use such as IV sets and stopcocks.

The recall includes two lots of Dual Luer Caps with product code 2C6250 and lot numbers 10043 and 10044 that were distributed to customers from June 19, 2013 to August 20, 2013.

Baxter International announced that it is cooperating with the FDA and has determined the cause of the problem. The problem has since been resolved.

Class I recalls are considered the most dangerous kind due to the reasonable probability that the use of the product will lead to serious and severe health consequences including death.

The FDA recommends that customers with affected lots immediately stop using the product and contact Baxter Healthcare Center for Service at 1-888-229-0001 to schedule a return for credit or replacement with caps from unaffected lots.

Written by: Russell Maas

Managing Editor & Senior Legal Journalist

Russell Maas is a paralegal and the Managing Editor of AboutLawsuits.com, where he has reported on mass tort litigation, medical recalls, and consumer safety issues since 2010. He brings legal experience from one of the nation’s leading personal injury law firms and oversees the site’s editorial strategy, including SEO and content development.

Image Credit: |



0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

Women across the U.S. are now pursuing product liability lawsuits and medical monitoring class action claims to secure compensation for potential brain tumor symptoms and side effects linked to the use of Depo-Provera.
A Texas mother is pursuing a lawsuit against Roblox and Discord, claiming the design of the apps allow sexual predators to access and groom young children.
Federal regulators are investigating whether Dupixent increases the risk of cutaneous T-cell lymphoma (CTCL), after more than 300 adverse event reports flagged cancer diagnoses among users. The FDA’s review comes as lawsuits are being pursued nationwide, alleging Sanofi and Regeneron failed to warn that the blockbuster eczema drug could either trigger or mask the rare blood cancer.